AMA wants drugmakers to report biologic shortages; India looks to revise GMP standards;

> The American Medical Association has written a letter to the FDA endorsing a proposal to extend to biologoic drugs the requirement that drug manufacturers let the agency know about anything that would interrupt supplies and potentially result in a shortage. Letter (PDF)

> The Drugs Controller General of India (DCGI) is reportedly asking for input about how to revise its good manufacturing practices (GMP) guidelines to make them equivalent to those of the World Health Organization. Report

> Ranbaxy Laboratories says it has gotten approval from Health Canada to sell a generic version of Pfizer's ($PFE) Aricept, a treatment for dementia in Alzheimer's patients. Release

> A Texas cancer doctor pleaded guilty and agreed to pay $1 million for illegally importing cancer drugs into the U.S. through Canada that were not approved for use here and then falsely charging U.S. health programs for them. Release

> Little Falls, NJ-based Cantel Medical has acquired Sterilator Co., a manufacturer of biological indicators and supplies for sterility assurance products based in Cuba, NY. Release

> Sanofi's ($SNY) Industrial Affairs division will act as contract manufacturing organization to manufacture clinical and commerical grade antisense oligonucleotide (ASO) compounds for Isarna Therapeutics of Munich, Germany. Release

And Finally... India has decided to maintain its current policy of allowing foreign investors to buy 100% of domestic firms, having abandoned its earlier suggestion of capping foreign ownership at 49%. Story